Literature DB >> 3925656

Topical nitroglycerin ointment in Raynaud's phenomenon.

M Fischer, B Reinhold, H Falck, M Török, K Alexander.   

Abstract

The purpose of the study was to evaluate the hemodynamics of nitroglycerin ointment in Raynaud's phenomenon. 22 patients (15 women and 7 men aged 25-75 years) suffering from Raynaud's phenomenon were investigated in a double-blind paradigm. Blood flow measurements were performed by venous occlusion plethysmography. Cardiac output was registered by means of impedance cardiography. 800 mg nitroglycerin ointment 2% was applied on one hand only. In the placebo group, finger blood flow, blood pressure, heart rate, and cardiac output did not change significantly. In the group receiving nitroglycerin, finger blood flow increased significantly from 21.6 +/- 6.0 to 31.7 +/- 7.0 ml/100 ml/min. Systolic blood pressure decreased from 126 +/- 4 to 118 +/- 3 mmHg. Cardiac output significantly decreased from 7.3 +/- 0.8 to 6.3 +/- 0.5 l/min. It is concluded that nitroglycerin ointment in Raynaud's phenomenon has a local and a systemic effect as well, because, on the one hand, cardiac output and blood pressure decreased whereas, on the other hand, the increase in finger blood flow was more marked in the treated hand than in the contralateral control fingers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925656

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  6 in total

1.  Shiny white patches of the arms and forehead.

Authors:  Jason Emer; Dean David George; Sebastian Bernardo; Harleen Sidhu
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

2.  Managing Raynaud's phenomenon.

Authors:  S Roath
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-12

3.  Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review.

Authors:  Olivia Qiu; Theresa Chan; Matthew Luen; Joseph E Cruz; Evelyn R Hermes-DeSantis
Journal:  Rheumatol Int       Date:  2018-08-22       Impact factor: 2.631

Review 4.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

6.  Vasodilators for primary Raynaud's phenomenon.

Authors:  Kevin Yc Su; Meghna Sharma; Hyunjun Jonathan Kim; Elizabeth Kaganov; Ian Hughes; Mohamed Hashim Abdeen; Jennifer Hwee Kwoon Ng
Journal:  Cochrane Database Syst Rev       Date:  2021-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.